Use of of Hypericum perforatum extract in treatment of acetic acid induced ulcerative colitis

گوارش، مجله انجمن متخصصين گوارش و كبد ايران

دوره 20 - شماره Supple.1

Article Type: Original Article
Abstract: Introduction: Inflammatory bowel disease comprises ulcerative colitis (UC) and Crohn's disease which a redefined as relapsing, chronic and remitting inflammatory disease of the large intestine. Although there are several drug regimens for the treatment of UC, but scientist pay more attention to use of medicinal plant. Therefore, the aims of this study were to investigate the effects of Hypericum perforatum on the histopathological and tissue malondialdehyde (MDA) level of colonic tissue in rat with induced UC. Methods: UC was induced by administration on of 2 ml of 3% acetic acid into the colon. Seventy rats were allocated randomly into seven equal groups. Groups I and II received 1 ml of 600 and 300 mg/kg H. perforatum extract orally per day; groups III and IV received 1 ml of 20 and 10% intra-colonic gel form of H. perforatum extract daily; group V as positive control received 2 ml of intra-colonic asacol; group VI was a negative control receiving 0.5 ml/kg of normal saline after induction of UC and group VII received just intra-colonic gel base. All animals were evaluated for histological changes and tissue MDA level at seven days after treatment. Results: A more healing effect and a reduction in MDA activity were detected in response to both drug forms. In trans-rectal administration, 20% gel form had a better healing response than 10% gel form and were prominently more on the seventh day of therapy. In oral administration of H. perforatum extract, the 600 mg/kg dosage had a better healing response than 300 mg/kg and was significantly more on the seventh day of therapy. Conclusion: This study demonstrated that the daily applications of H. perforatum extract in both topical and orally forms can relieve the UC. The healing, anti-inflammatory, and antimicrobial properties of H. perforatum could make it an appropriate drug choice for the treatment of UC. Further studies are required to confirm its clinical effectiveness in humans.